Dagmar Rosa-Bjorkeson
Chief Operating Officer bei MESOBLAST LIMITED
Vermögen: 110 805 $ am 31.03.2024
Profil
Dagmar Rosa-Bjorkeson is an Independent Director at Xencor, Inc. and a Director at New Jersey City University Foundation and Deirdres House.
They are also the Chief Operating Officer at Mesoblast Ltd.
Ms. Rosa-Bjorkeson previously served as an Independent Director at Intercept Pharmaceuticals, Inc. from 2021 to 2023.
They were the President-Biosimilars & EVP at Baxalta, Inc. from 2014 to 2016 and Vice President & Head-Multiple Sclerosis Business at Novartis Pharmaceuticals Corp.
from 1997 to 2014.
Ms. Rosa-Bjorkeson also held positions at Hoechst Pharmaceuticals Ltd.
as a Sales Representative, Mallinckrodt Medical, Inc. (US) as an Executive VP, Chief Strategy & Development Officer from 2017 to 2020, and Mallinckrodt Plc as the Chief Strategy & Corporate Development Officer from 2018 to 2020.
They have an undergraduate degree, a graduate degree, and an MBA from The University of Texas at Austin.
Ms. Rosa-Bjorkeson's current job(s) include Independent Director at Xencor, Inc., Director at New Jersey City University Foundation, Director at Deirdres House, and Chief Operating Officer at Mesoblast Ltd.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
XENCOR, INC.
0,01% | 20.06.2023 | 5 007 ( 0,01% ) | 110 805 $ | 31.03.2024 |
Aktive Positionen von Dagmar Rosa-Bjorkeson
| Unternehmen | Position | Beginn |
|---|---|---|
| XENCOR, INC. | Director/Board Member | 18.12.2019 |
| MESOBLAST LIMITED | Chief Operating Officer | 24.07.2020 |
| Deirdres House | Director/Board Member | - |
New Jersey City University Foundation
 New Jersey City University Foundation Other Consumer ServicesConsumer Services The New Jersey City University Foundation operates colleges and educational universities. The private company is based in New Jersey. | Director/Board Member | - |
Ehemalige bekannte Positionen von Dagmar Rosa-Bjorkeson
| Unternehmen | Position | Ende |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Director/Board Member | 08.11.2023 |
| MALLINCKRODT PLC | Corporate Officer/Principal | 01.01.2020 |
Mallinckrodt Medical, Inc. (US)
 Mallinckrodt Medical, Inc. (US) Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Medical, Inc. is a pharmaceutical company based in St. Louis. The American company manufactures pharmaceutical products. | Corporate Officer/Principal | 01.01.2020 |
| BAXALTA INC | Corporate Officer/Principal | 01.01.2016 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01.01.2014 |
Ausbildung von Dagmar Rosa-Bjorkeson
| The University of Texas at Austin | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| XENCOR, INC. | Health Technology |
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| MALLINCKRODT PLC | Health Technology |
| MESOBLAST LIMITED | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
| Hoechst Pharmaceuticals Ltd. | |
Novartis Sverige AB
 Novartis Sverige AB Pharmaceuticals: MajorHealth Technology Novartis Sverige AB trades pharmaceutical products. It offers products for the treatment of ADHD, multiple sclerosis, urticaria, allergic asthma, psoriasis, chronic obstructive pulmonary disorder, migraine, blood diseases, eye disorder, and other diseases. The company is headquartered in Kista, Sweden. | Health Technology |
New Jersey City University Foundation
New Jersey City University Foundation Other Consumer ServicesConsumer Services The New Jersey City University Foundation operates colleges and educational universities. The private company is based in New Jersey. | Consumer Services |
| Deirdres House | |
Mallinckrodt Medical, Inc. (US)
Mallinckrodt Medical, Inc. (US) Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Medical, Inc. is a pharmaceutical company based in St. Louis. The American company manufactures pharmaceutical products. | Health Technology |
